Zhongyuan Union Cell & Gene Engineering Corporation Overview
- Status
-
Public
- Employees
-
1,935
- Stock Symbol
-
600645
- Investments
-
12
- Share Price
-
$2.51
- (As of Friday Closing)
Zhongyuan Union Cell & Gene Engineering Corporation General Information
Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in The research, development, production and sales of cell detection preparation and storage, gene detection, in vitro diagnostic reagents and instruments, as well as the research, development, production and sales of biological genes, proteins, antibodies, pharmaceutical intermediates and experimental complexes.
Contact Information
Website
www.vcanbio.comCorporate Office
- Room 406, No. 45 Doungjiu Avenue
- Tianjin Airport Economic Zone
- Tianjin, 300304
- China
Corporate Office
- Room 406, No. 45 Doungjiu Avenue
- Tianjin Airport Economic Zone
- Tianjin, 300304
- China
Zhongyuan Union Cell & Gene Engineering Corporation Stock Performance
As of 13-Nov-2026, Zhongyuan Union Cell & Gene Engineering Corporation’s stock price is $2.51. Its current market cap is $1.18B with 468M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.51 | $2.60 | $2.39 - $4.79 | $1.18B | 468M | 10.3M | $0.03 |
Zhongyuan Union Cell & Gene Engineering Corporation Financials Summary
As of 30-Sep-2026, Zhongyuan Union Cell & Gene Engineering Corporation has a trailing 12-month revenue of $200M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,100,415 | 1,465,262 | 1,064,183 | 1,153,583 |
| Revenue | 199,552 | 202,320 | 220,951 | 224,700 |
| EBITDA | 25,401 | 41,142 | 35,415 | 34,986 |
| Net Income | 16,327 | 15,829 | 13,985 | 15,047 |
| Total Assets | 797,774 | 756,393 | 719,024 | 763,388 |
| Total Debt | 9,647 | 9,815 | 15,363 | 16,347 |
Zhongyuan Union Cell & Gene Engineering Corporation Signals
Zhongyuan Union Cell & Gene Engineering Corporation Investments & Acquisitions (12)
Zhongyuan Union Cell & Gene Engineering Corporation’s most recent deal was a Later Stage VC with Juventas (Drug Discovery) for . The deal was made on 25-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Juventas (Drug Discovery) | 25-Jun-2023 | Later Stage VC | Drug Discovery | ||
| Precision Medicine Industry Innovation Center | 03-Aug-2022 | Secondary Transaction - Private | Biotechnology | ||
| Zhongyuan Jisheng | 16-Feb-2022 | Merger/Acquisition | Biotechnology | ||
| Juventas (Drug Discovery) | 13-Dec-2018 | Early Stage VC | Drug Discovery | ||
| Origene | 13-Feb-2017 | Merger/Acquisition | Discovery Tools (Healthcare) |
Zhongyuan Union Cell & Gene Engineering Corporation ESG
Risk Overview
Risk Rating
Updated April, 30, 2024
27.64 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Biotechnology
Subindustry
of 444
Rank
Percentile
Zhongyuan Union Cell & Gene Engineering Corporation Exits (2)
Zhongyuan Union Cell & Gene Engineering Corporation’s most recent exit was on 19-Sep-2016 from Genetron Health. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Genetron Health | 19-Sep-2016 | Completed |
|
||
| Aeon Therapeutics | 01-Jan-2002 | Joint Venture | Completed |
|
Zhongyuan Union Cell & Gene Engineering Corporation Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Zhongyuan Jisheng | Shanghai, China | 2021 | |
| Origene | Rockville, MD | 1996 | |
| Shanghai Zhicheng Biotechnology | Pudong, China | 1995 |
Zhongyuan Union Cell & Gene Engineering Corporation FAQs
-
Where is Zhongyuan Union Cell & Gene Engineering Corporation headquartered?
Zhongyuan Union Cell & Gene Engineering Corporation is headquartered in Tianjin, China.
-
What is the size of Zhongyuan Union Cell & Gene Engineering Corporation?
Zhongyuan Union Cell & Gene Engineering Corporation has 1,935 total employees.
-
What industry is Zhongyuan Union Cell & Gene Engineering Corporation in?
Zhongyuan Union Cell & Gene Engineering Corporation’s primary industry is Biotechnology.
-
Is Zhongyuan Union Cell & Gene Engineering Corporation a private or public company?
Zhongyuan Union Cell & Gene Engineering Corporation is a Public company.
-
What is Zhongyuan Union Cell & Gene Engineering Corporation’s stock symbol?
The ticker symbol for Zhongyuan Union Cell & Gene Engineering Corporation is 600645.
-
What is the current stock price of Zhongyuan Union Cell & Gene Engineering Corporation?
As of 13-Nov-2026 the stock price of Zhongyuan Union Cell & Gene Engineering Corporation is $2.51.
-
What is the current market cap of Zhongyuan Union Cell & Gene Engineering Corporation?
The current market capitalization of Zhongyuan Union Cell & Gene Engineering Corporation is $1.18B.
-
What is Zhongyuan Union Cell & Gene Engineering Corporation’s current revenue?
The trailing twelve month revenue for Zhongyuan Union Cell & Gene Engineering Corporation is $200M.
-
What is Zhongyuan Union Cell & Gene Engineering Corporation’s annual earnings per share (EPS)?
Zhongyuan Union Cell & Gene Engineering Corporation’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process